PF-Atlas › Clinical Trials › NCT05246293
Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease.
Tofacitinib · Phase 2
Registry ID
NCT05246293
Phase
Phase 2
Status
Unknown
Drug / intervention
Tofacitinib
Sponsor
National Institute of Respiratory Diseases, Mexico
Start
2022-08-08
Enrollment
60
Locations
1
About this trial
Nowadays, no single drug is approved to treat rheumatoid arthritis-related interstitial lung disease (RA-ILD). The medical management of this clinical condition is empirical and controversial. There is preliminary data that tofacitinib may have a beneficial effect in treating RA-ILD. Tofacitinib may have a double role in treating RA-ILD: treat RA disease activity and an anti-fibrotic possible impact. Moreover, tofacitinib may be used as monotherapy for the treatment of rheumatoid arthritis (RA) This is a phase IIa clinical trial to evaluate the safety and tolerability of tofacitinib in RA-ILD patients.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT05246293 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.